Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Net Margin (2020 - 2023)

Gain Therapeutics has reported Net Margin over the past 4 years, most recently at 9310.11% for Q1 2023.

  • Quarterly results put Net Margin at 9310.11% for Q1 2023, down 203854.0% from a year ago — trailing twelve months through Dec 2023 was 40354.33% (down 4017658.0% YoY), and the annual figure for FY2023 was 40354.33%, down 4017658.0%.
  • Net Margin for Q1 2023 was 9310.11% at Gain Therapeutics, down from 5347.33% in the prior quarter.
  • Over the last five years, Net Margin for GANX hit a ceiling of 8434.07% in Q4 2021 and a floor of 46506.87% in Q1 2021.
  • Median Net Margin over the past 4 years was 8755.7% (2020), compared with a mean of 11697.8%.
  • Biggest five-year swings in Net Margin: crashed -3775117bps in 2021 and later skyrocketed 3923530bps in 2022.
  • Gain Therapeutics' Net Margin stood at 18116.65% in 2020, then soared by 147bps to 8434.07% in 2021, then crashed by -163bps to 5347.33% in 2022, then tumbled by -74bps to 9310.11% in 2023.
  • The last three reported values for Net Margin were 9310.11% (Q1 2023), 5347.33% (Q2 2022), and 7271.57% (Q1 2022) per Business Quant data.